Belite Bio, Inc(BLTE)Earnings, Financials & Key Ratios
BLTE•NASDAQ
Price updated Jun 19, 2026
AboutBelite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.Show more
- Revenue$0
- EBITDA-$84M-112.9%
- Net Income-$78M-114.7%
- EPS (Diluted)-2.31-95.8%
- ROE-16.94%+44.6%
BLTE Key Insights
Belite Bio, Inc (BLTE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 68.3% over 5 years
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BLTE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLTE Price & Volume
Belite Bio, Inc (BLTE) stock price & volume — 10-year historical chart
Loading chart...
BLTE Growth Metrics
Belite Bio, Inc (BLTE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-99.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-78.38%
Return on Capital
10 Years-35.61%
5 Years-38.09%
3 Years-33.22%
Last Year-18.37%
BLTE Recent Earnings
Belite Bio, Inc (BLTE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.34+43.3%
$0.60
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.38+32.1%
$0.56
Rev
—
$17M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.65-22.6%
$0.53
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.50-6.4%
$0.47
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.34vs $0.60+43.3% | — |
| Q2 2026 | Mar 2, 2026 | $0.38vs $0.56+32.1% | —vs $17M |
| Q4 2025 | Nov 10, 2025 | $0.65vs $0.53-22.6% | — |
| Q3 2025 | Aug 11, 2025 | $0.50vs $0.47-6.4% | — |
Based on last 12 quarters of dataView full earnings history →
BLTE Peer Comparison
Belite Bio, Inc (BLTE) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 REPL | 841.41M | 10.19 | -3.32 | -102.69% | 0.18 | |||
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare BLTE vs Peers
Belite Bio, Inc (BLTE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BLTE Income Statement
Belite Bio, Inc (BLTE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 5.74M | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
OpEx % of Revenue | - | - | - | - | - | - |
Selling, General & Admin | 2.06M | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
SG&A % of Revenue | - | - | - | - | - | - |
Research & Development | 3.69M | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
R&D % of Revenue | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -5.74M▲ 0% | -9.8M▼ 70.6% | -12.82M▼ 30.9% | -31.67M▼ 147.0% | -40M▼ 26.3% | -84.21M▼ 110.5% |
Operating Margin % | - | - | - | - | - | - |
Operating Income Growth % | - | -70.59% | -30.87% | -147% | -26.3% | -110.54% |
EBITDA | -5.73M | -9.77M | -12.62M | -31.27M | -39.55M | -84.21M |
EBITDA Margin % | - | - | - | - | - | - |
EBITDA Growth % | - | -70.57% | -29.24% | -147.71% | -26.47% | -112.93% |
D&A (Non-Cash Add-back) | 17K | 30K | 198K | 399K | 449K | 0 |
EBIT | -5.74M | -9.67M | -12.63M | -31.6M | -36.12M | -84.21M |
Net Interest Income | -9K | 5K | 7K | 49K | 3.72M | 0 |
Interest Income | 12K | 5K | 23K | 74K | 3.74M | 0 |
Interest Expense | 21K | 0 | 16K | 25K | 20K | 0 |
Other Income/Expense | -9K | 131K | 173K | 45K | 3.86M | 6.6M |
Pretax Income | -5.75M▲ 0% | -9.67M▼ 68.0% | -12.65M▼ 30.9% | -31.62M▼ 150.0% | -36.14M▼ 14.3% | -77.61M▼ 114.8% |
Pretax Margin % | - | - | - | - | - | - |
Income Tax | 1K | 0 | 0 | 9K | 6K | 0 |
Effective Tax Rate % | -0.02% | 0% | 0% | -0.03% | -0.02% | 0% |
Net Income | -5.75M▲ 0% | -9.67M▼ 68.0% | -12.65M▼ 30.9% | -31.63M▼ 150.1% | -36.14M▼ 14.3% | -77.61M▼ 114.7% |
Net Margin % | - | - | - | - | - | - |
Net Income Growth % | - | -68.02% | -30.85% | -150.09% | -14.26% | -114.73% |
Net Income (Continuing) | -5.75M | -9.67M | -12.65M | -31.63M | -36.14M | -77.61M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.62▲ 0% | -0.40▲ 35.5% | -0.63▼ 57.5% | -1.19▼ 88.9% | -1.18▲ 0.8% | -2.31▼ 95.8% |
EPS Growth % | - | 35.48% | -57.5% | -88.89% | 0.84% | -95.76% |
EPS (Basic) | -0.62 | -0.40 | -0.63 | -1.19 | -1.18 | -2.31 |
Diluted Shares Outstanding | 9.21M | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Basic Shares Outstanding | 9.21M | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Dividend Payout Ratio | - | - | - | - | - | - |
BLTE Balance Sheet
Belite Bio, Inc (BLTE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
Total Current Assets | 25.67M | 17.43M | 42.81M | 89.94M | 147.07M | 494.27M |
Cash & Short-Term Investments | 25.62M | 17.34M | 42.09M | 88.16M | 145.15M | 492.42M |
Cash Only | 25.62M | 17.34M | 42.09M | 88.16M | 31.68M | 352.93M |
Short-Term Investments | 0 | 0 | 0 | 0 | 113.47M | 139.49M |
Accounts Receivable | 40K | 23K | 19K | 867K | 594K | 718K |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | -19K | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 19K | 0 | 0 | 5K |
Total Non-Current Assets | 73K | 917K | 1.47M | 4.7M | 5.06M | 286.28M |
Property, Plant & Equipment | 66K | 94K | 1.38M | 1.3M | 965K | 777K |
Fixed Asset Turnover | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 31K | 3.23M | 3.99M | 4.92M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 280.17M |
Other Non-Current Assets | 7K | 823K | 57K | 166K | 103K | 425K |
Total Assets | 25.74M▲ 0% | 18.35M▼ 28.7% | 44.27M▲ 141.3% | 94.64M▲ 113.8% | 152.13M▲ 60.7% | 780.56M▲ 413.1% |
Asset Turnover | - | - | - | - | - | - |
Asset Growth % | - | -28.72% | 141.3% | 113.77% | 60.74% | 413.08% |
Total Current Liabilities | 972K | 1.64M | 2.1M | 3.63M | 6.05M | 9.88M |
Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 198K | 308K | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5K | 24K | 1.33M | 2.29M | 992K | 2.21M |
Current Ratio | 26.41x | 10.66x | 20.35x | 24.76x | 24.31x | 50.02x |
Quick Ratio | 26.41x | 10.66x | 20.35x | 24.76x | 24.31x | 50.02x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 31.81M | 31.81M | 668K | 578K | 261K | 188K |
Long-Term Debt | 31.81M | 31.81M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 668K | 578K | 261K | 188K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 32.78M | 33.44M | 2.77M | 4.21M | 6.31M | 10.07M |
Total Debt | 31.81M | 31.81M | 866K | 886K | 537K | 429K |
Net Debt | 6.19M | 14.46M | -41.22M | -87.27M | -31.14M | -352.5M |
Debt / Equity | - | - | 0.02x | 0.01x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - |
Interest Coverage | -273.48x | - | -789.50x | -1263.92x | -1805.90x | - |
Total Equity | -7.04M▲ 0% | -15.09M▼ 114.5% | 41.5M▲ 375.0% | 90.43M▲ 117.9% | 145.82M▲ 61.3% | 770.49M▲ 428.4% |
Equity Growth % | - | -114.48% | 374.97% | 117.9% | 61.25% | 428.38% |
Book Value per Share | -0.76 | -0.63 | 2.08 | 3.40 | 4.78 | 22.97 |
Total Shareholders' Equity | -7.04M | -15.09M | 41.5M | 90.43M | 145.82M | 770.49M |
Common Stock | 1K | 1K | 3K | 3K | 3K | 4K |
Retained Earnings | -17.56M | -27.22M | -39.87M | -71.5M | -107.65M | -185.26M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -44K | -196K | -392K | -374K | -660K | -536K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
BLTE Cash Flow Statement
Belite Bio, Inc (BLTE) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|
Cash from Operations | -4.44M | -7.47M | -11.46M | -29.84M | -29.23M | -36.99M |
Operating CF Margin % | - | - | - | - | - | - |
Operating CF Growth % | - | -68.26% | -53.3% | -160.4% | 2.02% | -26.52% |
Net Income | -5.75M | -9.67M | -12.65M | -31.63M | -36.14M | -77.61M |
Depreciation & Amortization | 17K | 30K | 198K | 399K | 449K | 464K |
Stock-Based Compensation | 1.36M | 1.53M | 1.48M | 3.82M | 8.99M | 38.92M |
Deferred Taxes | -1.39M | 0 | -1.91M | -4.69M | 0 | 0 |
Other Non-Cash Items | 1.39M | -8K | 1.91M | 4.69M | -3.66M | -1.31M |
Working Capital Changes | -69K | 640K | -491K | -2.43M | 1.13M | 2.55M |
Change in Receivables | 4K | 0 | -32K | -72K | 74K | -66K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Investing | -20K | -56K | -394K | -63K | -110.57M | -305.11M |
Capital Expenditures | -20K | -74K | -394K | -63K | -116K | -178K |
CapEx % of Revenue | - | - | - | - | - | - |
Acquisitions | 0 | 18K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -35K | 0 |
Cash from Financing | 28.06M | -583K | 36.96M | 75.96M | 83.59M | 663.23M |
Debt Issued (Net) | -2.32M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 30.29M | -583K | 37.99M | 77.19M | 42.24M | 292.86M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 86K | 0 | -1.03M | -1.23M | 41.36M | 370.37M |
Net Change in Cash | 23.6M▲ 0% | -8.27M▼ 135.1% | 24.75M▲ 399.1% | 46.07M▲ 86.2% | -56.48M▼ 222.6% | 321.25M▲ 668.8% |
Free Cash Flow | -4.46M▲ 0% | -7.55M▼ 69.2% | -11.85M▼ 57.0% | -29.9M▼ 152.3% | -29.39M▲ 1.7% | -37.17M▼ 26.5% |
FCF Margin % | - | - | - | - | - | - |
FCF Growth % | - | -69.16% | -57.02% | -152.28% | 1.72% | -26.48% |
FCF per Share | -0.48 | -0.31 | -0.59 | -1.12 | -0.96 | -1.11 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.77x | 0.91x | 0.94x | 0.81x | 0.48x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 1K |
Taxes Paid | 0 | 0 | 0 | 9K | 6K | 0 |
BLTE Key Ratios
Belite Bio, Inc (BLTE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -95.79% | -47.95% | -30.6% | -16.94% |
Return on Invested Capital (ROIC) | - | - | - | -1381.68% | -50.91% | -23.71% |
Debt / Equity | - | - | 0.02x | 0.01x | 0.00x | 0.00x |
Interest Coverage | -273.48x | - | -789.50x | -1263.92x | -1805.90x | - |
FCF Conversion | 0.77x | 0.77x | 0.91x | 0.94x | 0.81x | 0.48x |
Related:BLTE Dividend History·BLTE Revenue History·BLTE Price History·BLTE P/E History·BLTE Financial Ratios·BLTE Institutional Holders
BLTE Frequently Asked Questions
Belite Bio, Inc (BLTE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Belite Bio, Inc (BLTE) grew revenue by 0.0% over the past year. Growth has been modest.
Belite Bio, Inc (BLTE) reported a net loss of $66.0M for fiscal year 2025.
Dividend & Returns
Belite Bio, Inc (BLTE) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
Belite Bio, Inc (BLTE) had negative free cash flow of $10.6M in fiscal year 2025, likely due to heavy capital investments.